A Phase 1a Study of IMR-687 in Healthy Adult Volunteers
Phase of Trial: Phase I
Latest Information Update: 15 May 2017
At a glance
- Drugs IMR 687 (Primary)
- Indications Sickle cell anaemia
- Focus Adverse reactions; First in man
- Sponsors Imara Inc
- 15 May 2017 According to Imara Inc media release, company anticipates results from this study in the summer of 2017.
- 16 Nov 2016 According to an Imara Inc media release, first subject has been dosed in the study.
- 16 Nov 2016 Status changed from planning to recruiting, according to an Imara Inc media release.